Ordinary Annual General Meeting 2025

The Annual General Meeting of Evotec SE was held on Tuesday, 3 June 2025, at 10.00 a.m. (CEST), at CinemaxX Hamburg-Dammtor, Room 1, Dammtordamm 1, 20354 Hamburg, Germany as an in-person event.

If you wish to view our Annual General Meeting archive you can do so here.

Agenda

  1. Presentation of the approved annual financial statements and the consolidated financial statements of Evotec SE as of 31 December 2024, as approved by the Supervisory Board, the management reports for Evotec SE and the Group for the financial year 2024, the report of the Supervisory Board for the financial year 2024 and the comments by the Management Board regarding this information pursuant to Sections 289a, 315a of the German Commercial Code (Handelsgesetzbuch, HGB).
  2. Resolution discharging the members of the Management Board of liability for financial year 2024.
    2.1
    Dr Christian Wojczewski
    2.2 Aurélie Dalbiez
    2.3
     Dr Cord Dohrmann
    2.4. Dr Matthias Evers
    2.5
     Laetitia Rouxel
    2.6 Dr Craig Johnstone
    2.7
     Dr Werner Lanthaler
  3. Resolution discharging the members of the Supervisory Board of liability for financial year 2024.
  4. Resolution regarding the election of the auditor of the consolidated financial statements and the auditor of the sustainability report for financial year 2025 and of the auditor for any review of additional financial information during the year
    4.1
    Election of the auditor of the the consolidated financial statements and of the auditor for any review of additional financial information during the year
    4.2
    Election of the auditor of the sustainability report for financial year 2025
  5. Resolution to approve the Remuneration Report 2024
  6. Resolution on amending the Articles of Association to renew the option of holding virtual general meetings 
  7. Resolution on modifying the Share Performance Plan 2022 (modification of the authorisation to issue subscription rights to Management Board members of Evotec SE, members of management boards of affiliated companies in Germany and abroad and selected managers of Evotec SE and affiliated companies in Germany and abroad as part of a Share Performance Plan 2022; modification of the contingent capital available to satisfy subscription rights issued and exercised on the basis of this authorisation; amendment of the Articles of Association) and approval of the remuneration system for the Executive Board members.
    7.1 
    Replacement of the performance target “Revenue growth” by “Growth in adjusted Group EBITDA” in the Share Performance Plan 2022
    7.2
     Modification of the issue period for Share Performance Awards in the Share Performance Plan 2022 when Management Board members join in the course of the year
    7.3
     Modification of contingent capital
    7.4. Amendment to Article 5 (7) of the Articles of Association
    7.5. Approval of the remuneration system for Management Board members

Recording of the Management Speech

Please find below the recording of the Management Speech at the Annual General Meeting 2025.

If you cannot view the recording above, please watch the Annual General Meeting here

Convocation Documents for Download

Proxy Voting

Further Downloads

Countermotions

There were no countermotions.

Confirmation of the vote count pursuant to section 129 (5) sentence 1 AktG:

Pursuant to section 129 (5) sentence 1 of the German Stock Corporation Act (AktG), the person voting may request confirmation from the company within one month of the day of the Annual General Meeting as to whether and how his or her vote was counted. A request to this effect may be sent by e-mail to: evotec@linkmarketservices.eu


Hotline

Monday to Friday from 9 am to 5 pm by phone on +49 (0)89 8896906 610


Contact AGM Team

Evotec SE

Anja Ben Lekhal

Investor Relations Advisor

Manfred Eigen Campus

Essener Bogen 7

22419 Hamburg

T: +49 151 5187 1069

hauptversammlung@evotec.com 


Contact to the ADR Program

JPMorgan Chase & Co.

P.O. Box 64504

St. Paul, MN 55164-0504

USA

T: 800.990 1135 (from inside the USA)

T: +1.651.453 2128 (from outside the USA)

jpmorgan.adr@eq-us.com

TODO

Annual General Meeting Archive

Volker Braun

Investor Relations

vCard
Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.